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Background: Bloodstream infections (BSI) caused by Enterobacteriaceae show increasing frequency of resist-
ance to third-generation cephalosporin (3GC) antibiotics on the African continent but the mortality impact has
not been quantified.
Methods: We used historic data from six African hospitals to assess the impact of 3GC resistance on clinical
outcomes in Escherichia coli and Klebsiella pneumoniae BSI. We matched each bacteraemic patient to two unin-
fected patients. We compared outcomes between 3GC-susceptible and 3GC-resistant BSI and their respective
uninfected controls using Cox regression models.
Results: For 1431 E. coli BSI patients, we matched 1152 (81%) 3GC-susceptible and 279 (19%) 3GC-resist-
ant cases to 2263 and 546 uninfected inpatient controls. For 1368 K. pneumoniae BSI patients, we
matched 502 (37%) 3GC-susceptible and 866 (63%) 3GC-resistant cases to 982 and 1656 uninfected
inpatient controls. We found that 3GC-resistant E. coli had similar hazard ratios (HRs) for in-hospital mortal-
ity over their matched controls as compared to susceptible infections over their controls (ratio of HRs
1.03, 95% CI 0.73–1.46). Similarly, 3GC-resistance in K. pneumoniae BSI was not associated with mortality
(ratio of HR 1.10, 95% CI 0.80–1.52). Estimates of mortality impact varied by site without a consistent
pattern.
Conclusions: In a retrospective analysis, including the use of matched uninfected patients, there did not appear
to be an impact of 3GC-resistance on mortality in E. coli or K. pneumoniae BSI in African hospitals, as compared
with susceptible BSI with equivalent species. Better information on the actual use of antibiotics in treating
infections in African hospitals would improve these impact estimates.
VC The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/
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Introduction
Antibiotic resistance is a global challenge with major implications
for African countries where severe bacterial infections are com-
mon, but access to antibiotics is often limited.1,2 Bloodstream
infections (BSI) caused by the pathogens Escherichia coli and
Klebsiella pneumoniae are important contributors to neonatal,
child and adult morbidity and mortality in Africa.3–5 E. coli is a com-
mon cause of various community-acquired infections, whereas
K. pneumoniae typically causes hospital-acquired infections.3,6
High proportions of third-generation cephalosporin (3GC) resist-
ance amongst E. coli and K. pneumoniae BSI have been reported
from many African countries, often substantially exceeding the
proportions found in high-income settings.6–9 Clinically, 3GC-resist-
ance is important as it usually protects bacteria against almost all
antibiotics in the widely used penicillin and cephalosporin classes.
Furthermore, in most African hospitals, 3GC antibiotics represent
the most broad-spectrum class of antibiotics available, so patients
with 3GC-resistant infections often receive inadequate treatment.
Despite the increasing occurrence of 3GC-resistant BSI in Africa,
regional estimates of the clinical impact of this, or any, form of
antibiotic resistance on mortality and length of hospital stay (LOS)
are scarce.9
Methodologically, measuring the impacts of antibiotic-resistant
infections is challenging: there is a potential for confounding due
to underlying differences in patients acquiring drug-resistant infec-
tions as patients with drug-resistant infections are typically older
and sicker. To minimize such confounding, a two-step approach
can be applied, whereby the impact of having an infection is first
determined by comparing infected and uninfected-but-similar
patients, and then the additional impact of resistance is derived
from comparing these effect estimates between matched cohorts.
Studying all these differences gives the most complete description
of the impacts of a resistant infection.10 The comparison group for
measurements of impact of resistant infections can be either sus-
ceptible infections of the same type (a ‘replacement’ scenario,
meaning that the drug-resistant infection is hypothetically
replaced with a drug-susceptible infection) or no infection (a ‘non-
replacement’ scenario, meaning that the drug-resistant infection
hypothetically does not occur at all). Although most analyses use
the former, there is some evidence that some resistant BSI occur
under a non-replacement scenario, especially nosocomial infec-
tions,11 so both should be considered.
Given differences in populations, access to critical care and anti-
biotic availability, it is unclear whether existing estimates of the im-
pact of 3GC-resistance from high-income settings are relevant for
African countries. A systematic review found that very few studies
conducted in Africa have examined impacts relating to 3GC anti-
biotic resistance.9 A study in Senegal found that inpatient mortality
associated with ESBL-producing Enterobacterales infections was
double that associated with ESBL-negative infections, with 4 days
additional LOS in survivors.12 Single-site cohort studies of BSI
in Tanzanian children13 and Ethiopian adults14 have also found
substantial mortality impacts of ESBL-type resistance, though
these effects were described in very small groups of pooled
Enterobacterales infections.
In this study, we conducted a retrospective analysis of inpatient
data from six African hospitals to estimate the impact of 3GC-re-
sistance on mortality and LOS in patients with E. coli and
K. pneumoniae BSI. We attempted to minimize confounding due
to underlying disease and bias due to time-dependency and com-
peting events by basing our study design on the BURDEN study,
which was conducted in 11 European hospitals in 2008–9.15,16
We hypothesized that 3GC-resistant E. coli and K. pneumoniae BSIs
result in higher mortality and extended LOS compared with
3GC-susceptible infections caused by the same species.
Methods
Study setting
Six public hospitals or hospital complexes from six sub-Saharan African
countries were invited to participate in the study: (1) Jos University
Teaching Hospital, Jos, Nigeria; (2) Korle-Bu Teaching Hospital, Accra,
Ghana; (3) Centre Hospitalier National Universitaire de Fann and Centre
Hospitalier National d’Enfants Albert Royer, Dakar, Senegal; (4)
Parirenyatwa Hospital, Harare, Zimbabwe; (5) Kilifi County Hospital, Kilifi,
Kenya; and (6) Tygerberg Hospital, Cape Town, South Africa). These hospi-
tals were purposively selected based on appropriate quality of microbio-
logical data collection and geographical representation across sub-Saharan
Africa. Each hospital had on-site laboratory facilities and five had previously
published microbiological data on the local profile of antibiotic resistance in
Gram-negative BSI isolates.3,6,12,17–19 All laboratories participated in
national external quality assurance programmes, although the culture,
identification and antibiotic susceptibility testing methods varied between
sites. Cefotaxime susceptibility test results were interpreted based on
standard practice in participating laboratories, using either the CLSI
(five laboratories) or EUCAST (Senegal) breakpoints for Enterobacteriaceae,
as advised at the time of testing. Three laboratories (hospitals 1, 5 and 6)
performed routine detection of ESBLs by double disc synergy testing
and via the automated Vitek II system (BioMérieux, Marcy l’Etoile, France)
(see Table 1).
Antibiotic treatment practices
Most hospitals used either a 3GC or a combination of ampicillin and genta-
micin for suspected community-acquired BSI. Empirical therapy for
hospital-acquired BSI varied widely between hospitals (Table 1). No
patient-level data on actual antibiotic use was collected in this study.
Study design
All consecutive E. coli and K. pneumoniae BSI episodes and their 3GC-resist-
ance phenotype (susceptibility or resistance to cefotaxime) were identified
retrospectively from laboratory records using manual record review (hospi-
tals 1–4) or electronic laboratory database extraction (hospitals 5 and 6).
Inpatients with laboratory-confirmed monomicrobial BSI with cefotaxime
susceptibility results available were included, regardless of patient age or
the timing of specimen submission. We defined BSI episodes with blood
culturing performed within 48 h of admission as community-acquired,
thereafter infections were considered hospital-acquired. Repeat-positive
blood cultures within 10 days of the original episode were excluded. Each
site investigator selected the longest locally possible time-period within
which to identify BSI episodes, aiming to retrospectively collect data on at
least 50 consecutive E. coli and 50 K. pneumoniae BSI.
Selection of uninfected controls
For each BSI patient identified, two uninfected patients were selected
who were matched on age category [neonates (0–28 days), infants
(29–364 days), children (1–14 years) and adults (.14 years)], hospital ward
and month of admission. An additional matching criterion was that the
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time-to-bacteraemia for the BSI case (interval from admission to blood cul-
ture collection) to avoid immortal time bias.20 The uninfected controls were
manually identified from inpatient ward registers (hospital 1–3) or using
electronic admission registers (hospitals 4–6). If more than two non-
infected patients were eligible for matching, investigators selected those
with admission dates closest to that of the BSI patient. We included
patients with BSI when only a single suitable uninfected control could be
identified. For each patient, date of birth, date and ward of admission and
date and type of hospital outcome (discharge or in-hospital death) were
recorded. For patients with BSI, we additionally collected blood culture
date, BSI pathogen and 3GC-susceptibility result.
Statistical analysis
Following data cleaning, analyses were done in Stata 16.0 (StataCorp,
2019). Outcomes were time to inpatient mortality and LOS, with analyses
performed separately for each pathogen. Analysis of hospital inpatient
cohorts has the potential to introduce bias and confounding by LOS, co-
morbid illness or severity of disease.15,16,21 The use of multivariate Cox re-
gression models considering competing events, and using time since infec-
tion as analysis time for exposed and unexposed patients, is recommended
to minimize time-dependent bias.22 Cause-specific Cox regression models
with robust standard errors were used to evaluate the effect of 3GC-resist-
ance on in-hospital mortality and discharge, measured as hazard ratios
(HR). We did not collect data on co-morbid illness. Time at risk commenced
on the date of blood culture for the BSI case. For controls, time at risk com-
menced on the day of hospital stay corresponding to the number of days
between admission and blood culture for their matched bacteraemic case.
The proportional hazards assumption was assessed using Schoenfeld resid-
uals. The effect attributable to 3GC-resistance was ascertained as the ratio
of the hazard ratios for resistant and susceptible parallel cohorts.23 We also
performed sub-group analysis by site in order to gain an understanding of
heterogeneity of effects between sites. We also used Fine and Gray’s
extended Cox regression model to simultaneously consider discharge from
hospital and death as two possible competing events, and generated the
sub-distribution HR for death.24
Cumulative incidence of in-patient mortality and discharge from hos-
pital after BSI onset or enrolment of matches was generated accounting
for competing risks using the ‘stcompet’ command in Stata.25 Calculation
of the impact of resistance phenotype on LOS in days was obtained using a
generalized linear model with gamma distribution and log link function for
positively skewed data. The effect on LOS attributable to 3GC-resistance
Table 1. Participating institution demographics and identification of the study population
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was ascertained as the predicted marginal mean difference between re-
sistant and susceptible parallel cohorts, with a 95% CI obtained using the
linearization method to allow for violations of distributional assumptions.
Study approvals
Ethics approval and waiver of individual informed consent was granted by
the Health Research Ethics Committee at each site. Permissions to access
the laboratory and ward registers were obtained from the hospitals’ labora-
tory and facility managers, respectively.
Results
A total of 1431 E. coli BSI and 1368 K. pneumoniae BSI episodes
were identified from the six sites (Table 2), although two hospitals
(Kenya and South Africa) contributed much larger datasets (88%
of the total E. coli and 82% of the total K. pneumoniae BSI
patients). At all study sites, patients paid for blood culture sample
processing, except for the South African site where patients did not
pay for laboratory testing and in the Kenyan site where blood cul-
turing was funded by research grants. In most sites, these data
were collected between 2010 and 2017, except in one site
(Kenya), where data collection commenced in 2002. The microbio-
logical prevalence of 3GC-resistance ranged from 13% (in South
Africa) to 75% (in Ghana) for E. coli BSI (overall 20%) and from 53%
(in Nigeria) to 77% (in Senegal) for K. pneumoniae BSI (overall 63%;
see Table 2 for both organisms). The majority of E. coli infections
were community-acquired (72%) whereas K. pneumoniae infec-
tions were mainly hospital acquired (67%) (Table 2). Neonatal and
paediatric BSI predominated at hospitals in Nigeria and Ghana,
whereas adults contributed most BSI events from the hospitals in
Zimbabwe and South Africa, although blood culturing practices
were not conducted uniformly across age groups in several sites,
so we not interpret these results to represent underlying incidence
patterns of bacteraemia.
Hospital mortality
Crude in-patient mortality for all E. coli BSI was high at 33% (477/
1442) and varied substantially by country ranging from 16%
(Nigeria) to 44% (Kenya). For all K. pneumoniae, BSI mortality was
similarly high at 36% (489/1368), varying from 17% (Nigeria) to
54% (Kenya) (Table 2). Among fatal cases, the median interval
from blood culture sampling to death was 3 (IQR 1–8.5) days for
susceptible and 3 (IQR 1–9) days for resistant E. coli BSI and 5 (IQR
1–13) days for susceptible and 3 (IQR 1–9.5) days for resistant
K. pneumoniae BSI.
Figure 1 illustrates the dynamics of the competing outcomes
(‘death’ versus ‘discharge’) for E. coli BSI [3GC-susceptible and -re-
sistant (Figure 1a and b)] and for K. pneumoniae BSI (3GC-suscep-
tible and resistant [Figure 1c and d)] and their respective matched
patients. Most deaths in patients with bacteraemia occurred
early. Patients with both susceptible and resistant E. coli and
K. pneumoniae infections were discharged at a slower rate than
their respective controls, with a stronger effect in the latter.
In the analysis of E. coli bacteraemias, 30.9% (356/1152) of
patients with 3GC-susceptible infections died in hospital versus
10.0% (207/2056) of their matched controls. Amongst patients
with 3GC-resistant E. coli bacteraemia, 43.4% (121/279) of
patients died in hospital versus 12.8% (70/546) of their matched
controls. In the Cox regression model, the HRs for death as com-
pared with the respective controls were 2.82 (95% CI 2.10–3.79)
for resistant infections and 2.73 (95% CI 2.29–3.24) for susceptible
infections. The overall ratio of HRs for inpatient mortality in 3GC-re-
sistant versus 3GC-susceptible E. coli infection was 1.03 (95% CI
0.73–1.46; P"0.85, see Table 3).
In the analysis of K. pneumoniae bacteraemias, 33.7% (169/
502) of patients with 3GC-susceptible infections died in hospital
versus 9.8% (96/982) of their matched controls. Amongst patients
with 3GC-resistant K. pneumoniae bacteraemia 37.0% (320/866)
of patients died in hospital versus 9.7% (160/1656) of their
matched controls. In the Cox regression model, the HRs for death
as compared with the respective controls were 2.89 (95% CI 2.38–
3.50) for resistant infections and 2.61 (95% CI 2.03–3.37) for sus-
ceptible infections. The overall ratio of HRs for inpatient mortality
in 3GC-resistant versus 3GC-susceptible K. pneumoniae infection
was 1.10 (95% CI 0.79–1.51; P"0.54, see Table 3).
In the Fine and Gray competing risk models for inpatient death,
the sub-distribution HRs for all four types of infection were greater
than in the corresponding event-specific Cox models for mortality
(Table 3). This is because all forms of BSI were also associated with
prolonged hospital admission and this model combines the effects
of both prolonged admission and increased risk of mortality.
However, when comparing 3GC-resistant versus -susceptible
forms of both E. coli and K. pneumoniae, the results were similar to
the event-specific Cox models—there was no substantial effect of
3GC resistance in either E. coli BSI [ratio of sub-distribution HR 1.08
(95% CI 0.77–1.51)] or K. pneumoniae BSI [ratio of sub-distribution
HR 1.14 (95% CI 0.83–1.55), see Table 3].
Exploratory analysis of site-specific ratios of HRs for the mortal-
ity impact of resistant versus susceptible forms of E. coli and K.
pneumoniae are shown in Figure 2. The data for the hospitals in
Nigeria, Ghana and Senegal were pooled as these sites had insuffi-
cient data to display meaningful site-specific estimates. There was
some heterogeneity of site-specific mortality impact for both
pathogens, though confidence intervals were wide from the sites
providing small datasets.
We considered whether the timing of BSI onset (community-
acquired versus hospital-acquired) might have influenced out-
comes, as this influenced empirical antibiotic choices in most hos-
pitals, but no substantial mortality difference for either pathogen
was noted (data not shown).
Length of stay
On average, patients with BSI stayed in hospital for longer than
their matched controls. Patients with 3GC-resistant E. coli infec-
tions had an excess LOS of 1.9 days (95% CI #1.4 to 5.1); patients
with 3GC-susceptible had an excess LOS of 4.5 days (95% CI 3.1–
5.8). Patients with 3GC-resistant E. coli BSI stayed in hospital 0.80
times (95% CI 0.58–1.09) longer than those with susceptible infec-
tions. Amongst patients with K. pneumoniae BSI, 3GC-resistant
infections had an excess LOS of 6.2 days (95% CI 4.5–7.8); patients
with 3GC-susceptible infections had an excess LOS of 6.0 days
(95% CI 3.9–8.2). There was no evidence of longer LOS for patients
with 3GC-resistant BSI compared with susceptible BSI for either or-
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Age groups
In sub-analyses with stratification by age (Table 4), there was
no clear evidence of a mortality or LOS impact of 3GC resistance
in any specific age groups for either E. coli or K. pneumoniae.
Discussion
Using retrospective data from six hospitals across sub-Saharan
Africa, we produced an estimate of the mortality and LOS
associated with 3GC-resistance on this continent. Contrary to our
hypothesis, we found no significant additional mortality impact for
3GC-resistance in either E. coli (ratio of HR 1.03 95% CI 0.73–1.46)
or in K. pneumoniae (ratio of HR 1.10 95% CI 0.80–1.52) in a
retrospective matched parallel cohort study design. However, in
both organisms, when compared against uninfected patients,
both 3GC-susceptible and 3GC-resistant BSI did have a large im-
pact on mortality. The same was true for extended LOS; on aver-
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Figure 1. Cumulative incidence of inpatient death and hospital discharge for patients with susceptible (a) and resistant (b) E. coli BSI and with sus-
ceptible (c) and resistant (d) K. pneumoniae BSI, and respective controls. Time since admission is in days.










R-E. coli versus matched controls 2.82 (2.10–3.79) 0.51 (0.44–0.59) 4.10 (3.06–5.48) 1.9 (#1.4 to 5.1)
S-E. coli versus matched controls 2.73 (2.29–3.24) 0.54 (0.50–0.58) 3.81 (3.21–4.51) 4.5 (3.1–5.8)
R-E. coli versus S-E. colia 1.03 (0.73–1.46) 0.94 (0.79–1.11) 1.08 (0.77–1.51) 0.80 (0.59–1.09)
R-K. pneumoniae versus matched controls 2.89 (2.38–3.50) 0.47 (0.43–0.51) 4.55 (3.77–5.49) 6.2 (4.5–7.8)
S-K. pneumoniae versus matched controls 2.61 (2.03–3.37) 0.51 (0.46–0.57) 3.99 (3.11–5.12) 6.0 (3.9–8.2)
R-K. pneumoniae versus
S-K. pneumoniaea
1.10 (0.80–1.52) 0.92 (0.80–1.06) 1.14 (0.83–1.55) 1.01 (0.84–1.21)
Note: for Cox models, these are cause-specific hazard ratios, whilst for the Fine!Gray models, these are sub-distribution hazard ratios.
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extended LOS when compared with uninfected patients, but no
significant excess LOS could be attributed to 3GC-resistance for ei-
ther pathogen.
When we performed additional site-specific analyses, for E. coli,
the mortality impacts of 3GC-resistance at the single largest site
(South Africa) and in pooled data from three sites in West Africa
were close to 1.0, indicating no effect. By contrast, the mortality
impact for 3GC-resistance in E. coli at the next largest site (Kenya)
was somewhat higher, though still statistically non-significant
[ratio of HR 1.55 (95% CI 0.93–2.59)] and higher still at the site in
Zimbabwe, albeit with wide confidence intervals (ratio of HR 8.04
(95% CI 1.03–63.0). However, the situation for K. pneumoniae was
different; there was no suggestion of a mortality impact of 3GC-re-
sistance status either in South Africa (ratio of HR 0.92), Kenya
(ratio of HR 0.95) or Zimbabwe (ratio of HR 0.92) but there
appeared to be a sizable impact in pooled data from the three
smaller sites in West Africa [ratio of HR 6.21 (95% CI 1.77–21.80)].
Thus overall, there was some suggestion of mortality impacts of
3GC-resistance in E. coli and K. pneumoniae in some of the hospi-
tals, but there was consistently no apparent impact in the single
largest patient cohort from one hospital in South Africa. The het-
erogeneity among sites also suggests the overall pooled estimates
might be interpreted with caution.
To explain the absence of mortality impacts in our main
analysis, there are several possibilities. First, 3GC-susceptible
Gram-negative infections are often resistant to the recommended
empirical antibiotic agents, such as ampicillin and gentamicin,
which may increase mortality among patients with 3GC-suscep-
tible BSI and attenuate the differential mortality impact for
3GC-resistant versus -susceptible BSI. At the second largest data-
contributing site (Kilifi Hospital, Kenya), there is now substantial
resistance to the first line WHO-recommended antibiotics among
BSI isolates, causing delay in initiating effective therapy for many
3GC-susceptible BSI (personal communication, Dr Claire Gordon).
Similar patterns of resistance are seen in Malawi, where surveil-
lance of antibiotic resistance has also been performed over an
extended period.8 This might explain the similar mortality out-
comes between 3GC-resistant and 3GC-susceptible BSI.
Secondly, impacts of 3GC-resistant infections might only be evi-
dent when cephalosporin antibiotics are in widespread use and
there is limited access to other drug classes (such as quinolones,
aminoglycosides or carbapenems). Whilst cephalosporin antibiot-
ics were certainly in use at all the participating hospitals during
the study time-periods, retrospectively we cannot quantify their
use precisely. Future studies should prospectively gather antibiotic
susceptibility data and individual-level antibiotic use, to evaluate
the impact of appropriate versus inappropriate antibiotic use for
resistant infections in low-income settings.
A third possibility is that the patients included in this study were
unrepresentative of all patients experiencing bacteraemia caused
by E. coli and K. pneumoniae in these hospitals. Given the relatively
low monthly blood culturing rate in several of the participating
sites, there is potential for introduction of selection bias. There is no
way to retrospectively correct for this possibility, but future studies
should try to enforce standardized blood culture collection criteria
Table 4. Impact of 3GC resistance on E. coli and K. pneumoniae BSI mortality by age category (all sites pooled)
HR (95% CI)
Comparison Cox model (death) Cox model (discharge alive) Fine and Gray model (death)
Infants (,365 days)
R-E. coli versus S-E. coli 0.50 (0.14–1.86) 1.05 (0.87–1.26) 0.72 (0.40–1.30)
R-K. pneumoniae versus S-K. pneumoniae 2.31 (0.91–5.91) 0.93 (0.84–1.03) 1.56 (1.01–2.42)
Children (1–14 years)
R-E. coli versus S-E. coli 0.75 (0.03–22.41) 1.11 (0.86–1.43) 0.85 (0.37–1.98)
R-K. pneumoniae versus S-K. pneumoniae 0.10 (0.00–17.21) 0.73 (0.53–1.00) 0.84 (0.28–2.49)
Adults (.14 years)
R-E. coli versus S-E. coli 1.77 (0.37–8.36) 0.89 (0.80–0.98) 1.43 (0.87–2.34)
R-K. pneumoniae versus S-K. pneumoniae 0.96 (0.18–5.10) 1.02 (0.92–1.13) 0.92 (0.55–1.52)
Subgroup
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Figure 2. Impact of 3GC resistance on mortality in E. coli and K. pneumo-
niae bloodstream infection by country.
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and achieve adequate rates of blood culture performance.26 This
will be challenging whenever patients must self-fund blood cul-
tures costs, as is the case in most African hospitals.
A final possibility is that there is a genuine mortality difference
between 3GC-resistant and -susceptible BSI in African hospitals,
but that this difference is only small and hence this study was
underpowered to detect it against a high background mortality
rate. A large study in Thailand showed that pattern of results for
the pathogens examined here27; it is possible that a similarly small
excess mortality exists for these resistant infections in African
countries.
We modelled our study design on the BURDEN study, which
analysed impacts of E. coli and Staphylococcus aureus BSI in 11
European hospitals. That study found substantial impact of 3GC-
resistance in E. coli,15 but not for methicillin resistance in S. aur-
eus.16 There are several important differences between our study
and the BURDEN study in the level of data collection. The BURDEN
study prospectively gathered data on patient-level variables (such
as co-morbidity, in terms of the Charlson Co-morbidity Index)
which were used to adjust the relevant models. In our retrospect-
ive study, it was not possible to gather this level of detailed infor-
mation about individual patients from hospital case records, this is
a limitation of our study. The resulting lack of adjustment for
patient-level variables may also go some way to explaining our
findings of no effect of 3GC-resistance in these patients.
An important effect-modifier of the impact of AMR on clinical
outcomes, is early appropriate antibiotic treatment. In this study,
we were not able to collect individual patient data, but we did have
access to local guidelines for empirical prescribing of antibiotics for
treating suspected BSI. These guidelines differed widely between
participating hospitals. In particular, at the only site with routine
use of carbapenems or piperacillin/tazobactam and amikacin for
hospital-acquired sepsis (Tygerberg Hospital, South Africa), there
was no evidence of mortality impact attributable to 3GC-resist-
ance. This site also contributed most of the patients for this study.
For the five other hospitals, therapeutic options for 3GC-resistant
BSI were much more limited and access to appropriate antibiotics
was restricted to laboratory confirmation of ESBL-production
status, substantially delaying the onset of effective therapy.
This study has a number of important strengths. These include:
a modest degree of generalizability from the involvement of six
widely distributed African hospitals (albeit hospitals with unusually
good provision of microbiology services, as compared with other
regional hospitals) and representation of all age categories; use of
reliable microbiological data from externally accredited microbiol-
ogy laboratories; focus on a clearly defined form of infection (BSI)
in two important Gram-negative pathogens; and the use of an
analysis format designed to minimize bias associated with in-
patient datasets and time-dependent exposure. The large overall
numbers of patients included makes this by far the largest-ever
examination of the impacts of antibiotic resistance in African hos-
pitals. Limitations to this work are the retrospective collection of
data (which precluded data collection on antibiotic treatment and
potential confounders) and the inclusion of small numbers of BSI
episodes at four of the six participating hospitals. Whilst we have
made a first attempt to supply attributable mortality estimates
using data from multiple African countries, generation of further
data on the clinical impacts of antibiotic resistance and incidence
of infections across the African continent is imperative.
Conclusions
In laboratory and clinical data collected retrospectively from
African hospitals, we did not find statistically significant evidence
of additional mortality or LOS impacts associated with 3GC-resist-
ance in inpatients with bloodstream infections caused by E. coli
and K. pneumoniae. However, there were clear impacts of both
3GC-susceptible and -resistant BSI as compared with uninfected
patients. Further prospective studies would help to refine these
findings and reveal underlying mechanisms, including the role of
effective antibiotic therapy in preventing mortality.
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